vs
Orthofix Medical Inc.（OFIX）与Zurn Elkay Water Solutions Corp（ZWS）财务数据对比。点击上方公司名可切换其他公司
Zurn Elkay Water Solutions Corp的季度营收约是Orthofix Medical Inc.的1.9倍（$407.2M vs $219.9M），Zurn Elkay Water Solutions Corp净利率更高（10.3% vs -1.0%，领先11.3%），Zurn Elkay Water Solutions Corp同比增速更快（9.8% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 4.4%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Zurn Elkay Water Solutions是一家专业水资源管理解决方案提供商，主要生产销售商用给排水设备、饮用水系统、过滤产品及流量控制组件，服务北美及全球的商用、住宅、工业和公共基建领域，主打高效节水的可持续产品。
OFIX vs ZWS — 直观对比
营收规模更大
ZWS
是对方的1.9倍
$219.9M
营收增速更快
ZWS
高出7.9%
2.0%
净利率更高
ZWS
高出11.3%
-1.0%
两年增速更快
OFIX
近两年复合增速
4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $407.2M |
| 净利润 | $-2.2M | $42.1M |
| 毛利率 | 71.1% | 44.4% |
| 营业利润率 | 0.2% | 14.8% |
| 净利率 | -1.0% | 10.3% |
| 营收同比 | 2.0% | 9.8% |
| 净利润同比 | 92.4% | 15.7% |
| 每股收益（稀释后） | $-0.05 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXZWS
| Q4 25 | $219.9M | $407.2M | ||
| Q3 25 | $205.6M | $455.4M | ||
| Q2 25 | $203.1M | $444.5M | ||
| Q1 25 | $193.6M | $388.8M | ||
| Q4 24 | $215.7M | $370.7M | ||
| Q3 24 | $196.6M | $410.0M | ||
| Q2 24 | $198.6M | $412.0M | ||
| Q1 24 | $188.6M | $373.8M |
净利润OFIXZWS
| Q4 25 | $-2.2M | $42.1M | ||
| Q3 25 | $-22.8M | $61.8M | ||
| Q2 25 | $-14.1M | $50.5M | ||
| Q1 25 | $-53.1M | $43.6M | ||
| Q4 24 | $-29.1M | $36.4M | ||
| Q3 24 | $-27.4M | $43.5M | ||
| Q2 24 | $-33.4M | $46.0M | ||
| Q1 24 | $-36.0M | $34.3M |
毛利率OFIXZWS
| Q4 25 | 71.1% | 44.4% | ||
| Q3 25 | 72.2% | 44.1% | ||
| Q2 25 | 68.7% | 45.5% | ||
| Q1 25 | 62.8% | 46.6% | ||
| Q4 24 | 69.0% | 43.5% | ||
| Q3 24 | 68.7% | 46.2% | ||
| Q2 24 | 67.8% | 45.2% | ||
| Q1 24 | 67.5% | 45.5% |
营业利润率OFIXZWS
| Q4 25 | 0.2% | 14.8% | ||
| Q3 25 | -8.3% | 17.0% | ||
| Q2 25 | -7.9% | 17.5% | ||
| Q1 25 | -25.2% | 16.3% | ||
| Q4 24 | -5.3% | 13.3% | ||
| Q3 24 | -9.6% | 17.1% | ||
| Q2 24 | -12.5% | 17.5% | ||
| Q1 24 | -15.6% | 14.2% |
净利率OFIXZWS
| Q4 25 | -1.0% | 10.3% | ||
| Q3 25 | -11.1% | 13.6% | ||
| Q2 25 | -6.9% | 11.4% | ||
| Q1 25 | -27.4% | 11.2% | ||
| Q4 24 | -13.5% | 9.8% | ||
| Q3 24 | -13.9% | 10.6% | ||
| Q2 24 | -16.8% | 11.2% | ||
| Q1 24 | -19.1% | 9.2% |
每股收益（稀释后）OFIXZWS
| Q4 25 | $-0.05 | $0.24 | ||
| Q3 25 | $-0.57 | $0.36 | ||
| Q2 25 | $-0.36 | $0.29 | ||
| Q1 25 | $-1.35 | $0.26 | ||
| Q4 24 | $-0.76 | $0.21 | ||
| Q3 24 | $-0.71 | $0.25 | ||
| Q2 24 | $-0.88 | $0.27 | ||
| Q1 24 | $-0.95 | $0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $300.5M |
| 总债务越低越好 | — | $496.5M |
| 股东权益账面价值 | $450.0M | $1.6B |
| 总资产 | $850.6M | $2.7B |
| 负债/权益比越低杠杆越低 | — | 0.31× |
8季度趋势，按日历期对齐
现金及短期投资OFIXZWS
| Q4 25 | $82.0M | $300.5M | ||
| Q3 25 | $62.9M | $260.1M | ||
| Q2 25 | $65.6M | $201.9M | ||
| Q1 25 | $58.0M | $144.7M | ||
| Q4 24 | $83.2M | $198.0M | ||
| Q3 24 | $30.1M | $187.9M | ||
| Q2 24 | $26.4M | $162.7M | ||
| Q1 24 | $27.0M | $157.1M |
总债务OFIXZWS
| Q4 25 | — | $496.5M | ||
| Q3 25 | $157.2M | $496.4M | ||
| Q2 25 | $157.0M | $495.9M | ||
| Q1 25 | $156.9M | $495.8M | ||
| Q4 24 | $157.0M | $495.6M | ||
| Q3 24 | $118.5M | $495.6M | ||
| Q2 24 | $118.0M | $495.5M | ||
| Q1 24 | $118.2M | $495.4M |
股东权益OFIXZWS
| Q4 25 | $450.0M | $1.6B | ||
| Q3 25 | $442.5M | $1.6B | ||
| Q2 25 | $458.3M | $1.6B | ||
| Q1 25 | $458.3M | $1.5B | ||
| Q4 24 | $503.1M | $1.6B | ||
| Q3 24 | $525.9M | $1.6B | ||
| Q2 24 | $546.0M | $1.6B | ||
| Q1 24 | $570.3M | $1.6B |
总资产OFIXZWS
| Q4 25 | $850.6M | $2.7B | ||
| Q3 25 | $832.6M | $2.7B | ||
| Q2 25 | $837.2M | $2.7B | ||
| Q1 25 | $823.1M | $2.6B | ||
| Q4 24 | $893.3M | $2.6B | ||
| Q3 24 | $867.9M | $2.7B | ||
| Q2 24 | $882.0M | $2.7B | ||
| Q1 24 | $906.0M | $2.7B |
负债/权益比OFIXZWS
| Q4 25 | — | 0.31× | ||
| Q3 25 | 0.36× | 0.31× | ||
| Q2 25 | 0.34× | 0.32× | ||
| Q1 25 | 0.34× | 0.32× | ||
| Q4 24 | 0.31× | 0.31× | ||
| Q3 24 | 0.23× | 0.31× | ||
| Q2 24 | 0.22× | 0.31× | ||
| Q1 24 | 0.21× | 0.31× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $91.7M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | 2.18× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXZWS
| Q4 25 | $27.7M | $91.7M | ||
| Q3 25 | $12.4M | $101.3M | ||
| Q2 25 | $11.6M | $110.6M | ||
| Q1 25 | $-18.4M | $42.9M | ||
| Q4 24 | $23.7M | $63.6M | ||
| Q3 24 | $11.7M | $90.9M | ||
| Q2 24 | $9.0M | $85.1M | ||
| Q1 24 | $-18.6M | $53.9M |
自由现金流OFIXZWS
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | — | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXZWS
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXZWS
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXZWS
| Q4 25 | — | 2.18× | ||
| Q3 25 | — | 1.64× | ||
| Q2 25 | — | 2.19× | ||
| Q1 25 | — | 0.98× | ||
| Q4 24 | — | 1.75× | ||
| Q3 24 | — | 2.09× | ||
| Q2 24 | — | 1.85× | ||
| Q1 24 | — | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
ZWS
暂无分部数据
